Figure 3.
Figure 3. Cumulative incidence of second VAEs in patients continuing vs ceasing nilotinib after a first VAE using the Kaplan-Meier method. In the group initially continuing nilotinib (n = 14), hatches represent censoring for end of follow-up or nilotinib cessation. In the group initially stopping nilotinib (n = 11), hatches represent end of follow-up. Hazard ratio, 8.3; 95% confidence interval, 1.01-68; P = .019.

Cumulative incidence of second VAEs in patients continuing vs ceasing nilotinib after a first VAE using the Kaplan-Meier method. In the group initially continuing nilotinib (n = 14), hatches represent censoring for end of follow-up or nilotinib cessation. In the group initially stopping nilotinib (n = 11), hatches represent end of follow-up. Hazard ratio, 8.3; 95% confidence interval, 1.01-68; P = .019.

Close Modal

or Create an Account

Close Modal
Close Modal